Early lab and animal tests show that a new form of insulin could help prevent sudden drops in blood sugar. The modified insulin, called NNC2215, has a switch that can open and close in response to blood sugar. When blood sugar levels are high, the switch opens, and the insulin becomes more active, removing the sugar
Risk of new diabetes diagnosis was higher compared with non-COVID respiratory infections Children and teens had an increased risk of being diagnosed with type 2 diabetes after COVID-19 infection, a retrospective cohort study of over 600,000 youth suggested. Adolescents 10 to 19 years old had a 55% higher risk for a new diagnosis of type
Researchers of University of Birmingham have shown that blood vessels produce a protein called CLEC14A that inhibits bone formation Scientists have identified a protein that blocks the activity of bone-forming cells (osteoblasts) by stopping them from maturing during the journey to sites of bone formation, a new study has found. In a paper published in Communications
Authors say findings support considering convalescent plasma deployment for future infectious diseases emergencies A new study led by researchers at Johns Hopkins Bloomberg School of Public Health estimates that thousands of lives could have been saved during the first year of the COVID-19 pandemic if convalescent plasma had been used more broadly, particularly in outpatients
Study marks the first time these side effects were reported in children Researchers at Children’s Hospital of Philadelphia (CHOP) revealed for the first time that children, adolescents and young adults may experience very rare neurological issues of paraparesis and quadriparesis following chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy used to treat B-cell Acute
Research analysis reveals risk of cardiac events also varied by blood type and stays elevated for years after diagnosis A history of COVID-19 can double the risk of heart attack, stroke or death according to new research led by Cleveland Clinic and the University of Southern California. The study found that people with any type of COVID-19
Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer’s decision is based on the totality of
NIH-supported findings pave the way for genetic testing, clinical trials, and therapy development Scientists at the National Institutes of Health (NIH) and their colleagues have identified a gene responsible for some inherited retinal diseases (IRDs), which are a group of disorders that damage the eye’s light-sensing retina and threatens vision. Though IRDs affect more than
When the U.S. Food and Drug Administration (FDA) announced in November 2023 that it was investigating a link between receiving CAR T therapy and developing secondary cancers later on, it spurred uncertainty for patients and researchers alike. As many of the more than 30,000 patients who have received the life-saving treatment face new questions about
Researchers isolated SARS-CoV-2 strains, which are drug resistant with mutations to the nsp12 protein that is the target of remdesivir and another variant with mutations to the nsp5 protein, the target of Paxlovid. These mutations help the virus persist in people with compromised immunity despite common antiviral treatments. Individuals with compromised immunity and persistent COVID-19
